SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-084520
Filing Date
2023-03-30
Accepted
2023-03-30 07:41:30
Documents
14
Period of Report
2023-03-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d490816d8k.htm   iXBRL 8-K 27037
2 EX-99.1 d490816dex991.htm EX-99.1 10519
6 GRAPHIC g490816g71l28.jpg GRAPHIC 11582
  Complete submission text file 0001193125-23-084520.txt   177439

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tcrt-20230329.xsd EX-101.SCH 2838
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrt-20230329_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrt-20230329_pre.xml EX-101.PRE 10804
8 EXTRACTED XBRL INSTANCE DOCUMENT d490816d8k_htm.xml XML 3229
Mailing Address 8030 EL RIO STREET HOUSTON TX 77054
Business Address 8030 EL RIO STREET HOUSTON TX 77054 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

IRS No.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 23777169
SIC: 2834 Pharmaceutical Preparations